A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase III, randomized, multicenter, open-label clinical trial designed to compare
RC48-ADC to physician choice standard treatment in participants with human epidermal growth
factor receptor 2 (HER2)-overexpression locally advanced or metastatic gastric cancer.